No drug targets autism’s core symptoms, but medications from antipsychotics to leucovorin can address irritability, sleep, attention, and other co-occurring challenges.
Xavier Amador explains how the LEAP communication strategy helps clinicians build trust with patients whose anosognosia makes them unable to recognize their own illness.
A placebo-controlled trial finds mirtazapine modestly improves sleep in older adults, but daytime drowsiness and confusion caused dropout in a notable minority of patients.
How long should you wait before concluding that antipsychotic-related sedation isn’t going to resolve on its own? A new meta-analysis finally puts a number on it.
Dr. Aiken is the Editor in Chief of The Carlat Psychiatry Report; director of Psych Partners. He maintains a private practice combining medication and therapy along with evidence-based complementary and alternative treatments; and Assistant Professor NYU Langone Department of Psychiatry. He has worked as a research assistant at the NIMH and a sub-investigator on clinical trials, and conducts research on a shoestring budget out of his private practice. Follow him on Twitter and find him on LinkedIn.